Force, J. M., Heymach, J. V., Beaudry, B., Wang, A. C., Baker, C., Ryan, A., … Soker, S. (n.d.). Effects of the VEGFR-2 Tyrosine Kinase Inhibitor ZD6474 and Docetaxel on Circulating Endothelial Cells (CEC): Implications for Use as a Surrogate Marker. Presented at the Proc AACR/NCI/EORTC Mol Targ and Canc Therapeutics.

Force, J. M., J. V. Heymach, B. Beaudry, A. C. Wang, C. Baker, A. Ryan, J. Folkman, and S. Soker. “Effects of the VEGFR-2 Tyrosine Kinase Inhibitor ZD6474 and Docetaxel on Circulating Endothelial Cells (CEC): Implications for Use as a Surrogate Marker,” n.d.

Force JM, Heymach JV, Beaudry B, Wang AC, Baker C, Ryan A, et al. Effects of the VEGFR-2 Tyrosine Kinase Inhibitor ZD6474 and Docetaxel on Circulating Endothelial Cells (CEC): Implications for Use as a Surrogate Marker. In.

Force, J. M., et al. Effects of the VEGFR-2 Tyrosine Kinase Inhibitor ZD6474 and Docetaxel on Circulating Endothelial Cells (CEC): Implications for Use as a Surrogate Marker.

Force JM, Heymach JV, Beaudry B, Wang AC, Baker C, Ryan A, Folkman J, Soker S. Effects of the VEGFR-2 Tyrosine Kinase Inhibitor ZD6474 and Docetaxel on Circulating Endothelial Cells (CEC): Implications for Use as a Surrogate Marker.